ClinicalTrials.gg
Not yet recruitingNCT07946224Updated Nov 18, 2026

Comparison of Breast Acoustic CT and Automated Breast Ultrasound in Women With Unilateral Untreated Breast Cancer

An interventional study of QT Scanner: Quantitative Transmission Ultrasound Breast Imaging System and ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUS in Breast Cancer, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 65 studies in Breast Neoplasms by Stanford University — 6 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Stanford University.

Planned enrollment
22nd of 46
40 · median 40
Started
2027
the only one that year
No phase
24 of 65
4 open now
Registered
65th of 65
by date

Among the 65 studies in Breast Neoplasms by Stanford University, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2027, is one of 24 with no phase, and was the 65th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 65 studies in Breast Neoplasms by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Breast Neoplasms by Stanford University, or all of them as a file.
02

Study summary

This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unilateral untreated breast cancer evaluated by breast MRI
  2. Participants' age range ≥18 years old
  3. Ability to understand and the willingness to provide written .
  4. Female gender
  5. Dense Breast composition
  6. Breast MRI available for reference comparison
  7. Able to undergo and ABUS imaging prior to definitive surgery or therapy.

Exclusion criteria

Exclusion Criteria:

  1. Prior mastectomy
  2. Bilateral breast cancer
  3. Concurrent use of agents
  4. Active breast infection, open wound, or skin condition involving the breast that would interfere with imaging.
  5. Breast size or body habitus incompatible with or ABUS image acquisition. i. Breasts with cup size A through DDD. Up to 400lbs of patient weight is supported.
  6. Non-dense breast composition
  7. Pregnant
  8. Breast feeding
  9. Receipt of chemotherapy, endocrine therapy, or radiation therapy before QT/ABUS imaging
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    QTI Breast Acoustic CT™ Scanner [QT Imaging] (QT), and Automated Breast Ultrasound (ABUS)

    Each participant will undergo one (1) imaging examination using the investigational QT Scanner and one (1) imaging examination using the FDA-cleared Invenia™ Automated Breast Ultrasound System (ABUS).

    Device: QT Scanner: Quantitative Transmission Ultrasound Breast Imaging System · Device: ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUS

Interventions

  • DeviceQT Scanner: Quantitative Transmission Ultrasound Breast Imaging System

    QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS)

  • DeviceABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUS

    ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner.

06

What researchers measure

Primary outcomes

  1. Number of Additional Breast Cancer Lesions Detected

    The number of additional contralateral and ipsilateral breast cancer lesions detected using the QT scanner and ABUS as reported by study radiologists in women with dense breast tissue and newly diagnosed unilateral breast cancer.

    Time frame: Baseline

  2. BI-RADS Assessment

    Radiologists' diagnostic assessment of contralateral and ipsilateral breast cancer lesions identified using the QT Scanner and ABUS, as measured using the Breast Imaging Reporting and Data System (BI-RADS) classification categories.

    Time frame: Baseline

  3. Numerical Likelihood of Malignancy

    Radiologists will assess the likelihood of malignancy for contralateral and ipsilateral breast cancer lesions detected by QT Scanner and ABUS. Diagnostic confidence will be measured using the numerical likelihood-of-malignancy estimates assigned to identified lesions.

    Time frame: Baseline

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 2,668 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,778 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 18, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946224
Collaborators
QT Imaging Holdings, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

David Marcellus
Contact
dmarcel2@stanford.edu
650-723-4547
Steven P Poplack
principal investigator · Stanford University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion